From: Treatment of hepatitis C genotype 1 patients with severe fibrosis or compensated cirrhosis: the telaprevir early access program in patients from Romania
Percent HCV RNA not detected
Week 4 (RVR)
Week 4+12 (eRVR)
Week 12
Treatment-naïve (n=30)
73%
70%
93%
Prior relapser (n=156)
85%
81%
94%
Prior partial responder (n=6)
100%
83%
Prior null responder (n=15)
80%
Overalla (n=209)
79%
92%